Uroial Plus in the Management of Infections and Urinary Symptoms Associated With Ureteral Stents

Double-blind randomised interventional pilot study. To evaluate whether therapy with UroialTM Plus has a role in rebalancing homeostasis in ureteral stent patients, improving symptoms related to the presence of the ureteral stent in place. Ureteral stent patients will be randomised into two groups: * the experimental group will receive UroialTM Plus sachets, one sachet daily at bedtime after urinating, for 30 days * the control group will receive a placebo, one sachet daily in the evening before going to bed after urinating, for 30 days. At each visit, the investigator will assess the possible occurrence of urinary symptoms, their severity and their impact on quality of life by administering the following questionnaires: IPSS, USSQ, AIA, SF-36, VAS, EQ-5D-5L.